52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager

Autor: S. Basnet, J.M. Santos, D.C.A. Quixabeira, J. Clubb, S. Grönberg-Vähä-Koskela, S. Pakola, T. Kudling, C. Heiniö, R. Havunen, V. Cervera-Carrascon, S. Sorsa, M. Anttila, A. Kanerva, A. Hemminki

Publikováno v: Immuno-Oncology and Technology. 16:100157

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3ddaa54f4464c11cbd4bc1fd4b7f8be
https://doi.org/10.1016/j.iotech.2022.100157

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

Autor: Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Kudling T; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Arias V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Jalkanen K; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Monberg T; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Khammari A; Department of Dermatology, Nantes University, CHU Nantes, CIC1413, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France., Dreno B; Nantes University, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France., Svane IM; National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark., Block MS; Mayo Clinic Cancer Center, Minnesota, Rochester, USA., Adamo DA; Mayo Clinic Cancer Center, Minnesota, Rochester, USA., Mäenpää J; Docrates Cancer Center, Helsinki, Finland.; Faculty of Medicine and Medical Technology, and Cancer Center, Tampere University and University Hospital, Tampere, Finland., Kistler C; TILT Biotherapeutics Ltd, Helsinki, Finland., Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki O; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Department of Urology, Helsinki University Hospital, Helsinki, Finland., Kanerva A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd, Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. akseli.hemminki@helsinki.fi.; TILT Biotherapeutics Ltd, Helsinki, Finland. akseli.hemminki@helsinki.fi.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland. akseli.hemminki@helsinki.fi.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Nov 06; Vol. 43 (1), pp. 297. Date of Electronic Publication: 2024 Nov 06.